SARM1 and peripheral neuropathy: In addition, SARM1 inhibitors are currently under clinical development for treatment of neurodegenerative conditions, including multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, optic neuropathies, DPN, and chemotherapy-induced peripheral neuropathy (33, 34).